CANCER SURVEILLANCE USING HEALTH CLAIMS-BASED DATA SYSTEM Release Date: November 12, 1998 PA NUMBER: PA-99-015 P.T. National Cancer Institute National Institute of Dental and Craniofacial Research Agency for Health Care Policy and Research PURPOSE This PA replaces PA-95-069, which was published in the NIH Guide, Volume 24, Number 20, June 2, 1995. The Division of Cancer Control and Population Sciences (DCPPS), National Cancer Institute (NCI), the National Institute of Dental and Craniofacial Research (NIDCR), and the Agency for Health Care Policy and Research (AHCPR) invite investigator-initiated grant applications for research to investigate the utility of health claims information as a reporting source for assessing the national cancer burden. Health claims include secondary data sources, for example fee- for-service insurance bills, managed care encounter data, and discharge summaries. Utility is broadly defined to include topics such as the use of health claims information to estimate patterns of care, outcomes of care, and effects of cancer therapies. Responses to this program announcement (PA) would initiate mechanisms to expand understanding of the capability of and methods needed to use claims data for cancer surveillance as well as applying these findings to the claims data in order to assess all aspects of cancer surveillance, such as cancer screening, incidence, treatment, and outcomes. The NIDCR's specific interests focus on health claims-based data as related to oral and pharyngeal cancers or the oral complications of cancer therapies. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Cancer Surveillance Using Health Claims-Based Data Systems, is related to the priority area of cancer surveillance and data systems. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202- 512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. MECHANISM OF SUPPORT Support of this program will be through the research project grant (R01) mechanism. Applicants will be responsible for the planning, direction, and execution of the proposed project. Awards will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement. RESEARCH OBJECTIVES The objectives of this PA are to encourage investigators to submit applications to investigate the utility of health claims information as a reporting source for assessing the national cancer burden. Health claims include secondary data sources such as fee-for-service insurance bills for medical, dental, rehabilitative, or other health care services, Medicare, Medicaid, and private managed care encounter data, data bases with multiple payers such as the Healthcare Cost and Utilization Project (HCUP) data base, and discharge summaries. Utility is broadly defined to include topics such as the use of health claims information to estimate patterns of care, outcomes of care, and effects of cancer therapies. Examples of research questions that could be addressed concerning the use of health claims information for cancer surveillance include, but are not limited to, the following: 1. Can claims data be used to assess practice patterns for cancer directed treatment immediately following diagnosis and for long-term follow-up and treatment over the course of the disease ? Using the claims data, what are the patterns of cancer for persons with specific cancers? What is the pattern for end-of-life care? What factors influence the care received at end-of-life? How are treatment patterns and outcomes affected by the use of carve-out contracts for cancer treatment? 2. What is the availability and completeness of encounter data from managed care settings? Do comparisons of data collected by health claims-based systems versus registries differ depending on the reimbursement system (fee-for-service claims vs. "managed care.")? 3. Using claims data, what are the long-term complications for cancer survivors as sequellae to their cancer treatment? 4. Can claims data be used to assess the use of diagnostic tests? Using claims data, how are diagnostic tests used? How can health claims-based data systems be used to track the emergence of new technologies for detecting, diagnosing, or treating cancer or pre-cancerous conditions? Can these data be used to develop an evaluation of the introduction of health care innovations related to cancer? 5. How can health claims-based data systems contribute to the identification of environmental causes of cancer, such as cluster analysis of incidence in small areas. 6. To what extent do health claims-based data systems provide additional information than what is routinely collected by cancer registries? Can claims data be used to assess cancer recurrence or metastasis? Can claims data be used to augment the case ascertainment of cancer registries? 7. Do dental claims data provide useful supplementary data, especially as regards oral cancer detection or treatments or the prevention and treatment of oral complications of radiation or chemotherapy? Do health claims-based data reveal how patterns of cancer-related oral care differ for cancer patients who have medical health insurance coverage only, as compared with cancer patients whose health insurance includes supplemental dental benefits? 8. Does encounter data in managed care settings permit assessment of whether the oral health services provided include screening for oral cancers or services involved in the prevention or treatment of oral complications of cancer treatments? Other issues to be addressed in regard to the above questions include the identification of data that are currently unavailable from a cancer registry, such as SEER, that are available in health claims-based data systems, the identification of barriers including cost that must be overcome to add health claims data to registry data, and the identification of questions concerning health claims data, such as costs considerations. Use of health claims-based systems to identify cancer burdens in special populations, such as minority populations (African Americans, Hispanics, Native Americans, Native Alaskans, Asian Americans and Pacific Islanders) and the underserved (low-income groups, blue-collar groups) is encouraged. The use of claims data to assess population- based cancer incidence and survival rates has been assessed in numerous earlier studies and is not a priority of this PA. Also, the confidentiality issues associated with the use of claims-based data, as well as any other databases proposed, should be addressed in regard to any of the above questions. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH and AHCPR that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. AHCPR follows these guidelines as applicable. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. POLICY AND GUIDELINES ON THE INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of NIH and AHCPR that children (i.e., individuals under the age of 21) must be included in all human subjects research, conducted or supported by the NIH, unless there are clear and compelling scientific and ethical reasons not to include them. This policy applies to all initial (Type 1) applications submitted for receipt dates after October 1, 1998. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects" that was published in the NIH Guide for Grants and Contracts, March 6, 1998, and is available at the following URL address: http://www.nih.gov/grants/guide/notice-files/not98-024.html APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/95) and will be accepted at the standard application deadlines as indicated in the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301/710-0267, E-mail: [email protected]. The title and number of the program announcement must be typed in Section 2 on the face page of the application. Applicants kits are also available at: http://www.nih.gov/grants/forms.htm. An applicant planning to submit an application requesting $500,000 or more in direct costs for any year is advised that he or she must contact Institute or Center program staff listed in the INQUIRES section of this PA before submitting the application. See NIH policy at http://www.nih.gov/grants/guide/notice-files/not98-030.html. The completed original application and five legible copies must be sent or delivered to: CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) REVIEW CONSIDERATIONS Applications will be assigned on the basis of established Public Health Service referral guidelines. Applications will be reviewed for scientific and technical merit in accordance with the standard NIH and AHCPR peer review procedures. Following scientific-technical review, the applications may receive a second-level review by the appropriate national advisory council. Review Criteria The goals of the supported research are to advance our understanding of biological systems, improve the control of disease, improve health care services, and enhance health. The reviewers will comment on the following aspects of the application in their written critiques in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered by the reviewers in assigning the overall score weighting them as appropriate for each application. Note that the application does not need to be strong in all categories to be judged likely to have a major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward. 1. Significance. Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? 2. Approach. Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? 3. Innovation. Does the project employ novel concepts, approaches or method? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? 4. Investigator. Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? 5. Environment. Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? The initial review group will also examine: the appropriateness of proposed project budget and duration; the adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research and plans for the recruitment and retention of subjects; the adequacy of plans for including children as appropriate for the scientific goals of the research, or justification for exclusion; the provisions for the protection of human and animal subjects; and the safety of the research environment. AWARD CRITERIA Applications will compete for available funds with all other approved applications assigned. The following will be considered in making funding decisions: Quality of the proposed project as determined by peer review, availability of funds, and program priority. INQUIRIES Inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Joan Warren, Ph.D. Applied Research Branch National Cancer Institute Executive Plaza North, Room 313 Bethesda, MD 20892 Telephone: (301) 496-5184 FAX: (301) 435-3710 Email: [email protected] Patricia S. Bryant, Ph. D. Division of Extramural Research National Institute of Dental and Craniofacial Research 45 Center Drive, Room 4AN-24E Bethesda, MD 20892-6402 Telephone: (301) 594-2095 FAX: (301) 480-8318 Email: [email protected] Bernard Friedman, Ph.D. Agency for Health Care Policy and Research 2101 East Jefferson Street, Suite 605 Rockville, MD 20852 Telephone: (301) 594-6819 Email: [email protected] Direct inquiries regarding fiscal matters to: Bill Wells Grants Administration Branch National Cancer Institute Executive Plaza South Bethesda, MD 20892 Telephone: (301) 496-7800 FAX: (301) 496-4801 Email: [email protected] Martin R. Rubinstein Grants Management Branch National Institute of Dental Research 45 Center Drive, Rm 4AN44A, MSC 6402 Bethesda, MD 20892-6402 Telephone: (301) 594-4800 FAX: (301) 480-8301 Email: [email protected] Mabel Lam Agency for Health Care Policy and Research 2101 East Jefferson Street, Suite 601 Rockville, MD 20852 Telephone: (301) 594-1447 X1165 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.399, Cancer Control Research, 93.121, Oral Health Research and 93.226. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 67, Subpart A, and 45 CFR Part 74 and part 92. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke- free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||